Summer 2027
Posted on 8/31/2026
Global healthcare company offering pharma, devices.
$23.50 - $52.50/hr
No H1B Sponsorship
Cincinnati, OH, USA
Hybrid
Hybrid work is required in Cincinnati.
Bachelor's, Master's
See people who can refer or advise you
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.
Johnson & Johnson's stock upside is being underestimated as investors focus narrowly on STELARA's patent cliff, according to a new analysis. The drug now represents just 4% of the Innovative Medicine portfolio, whilst the remaining 96% is growing at over 14%. The company operates 28 different billion-dollar platforms, demonstrating diversification beyond single-product dependency. Under baseline assumptions—revenue compounding at 6.8% annually, net margin improving from 22% to 24%, and P/E multiple compressing from 31.3x to 26.6x—the analysis projects upside over three years. If net margin returns to its three-year average of 29%, upside could expand further. The most significant drag comes from multiple compression; holding the P/E flat at current levels would lift total upside to 35%. Management's goal to become the leading oncology company by 2030, targeting over $50 billion in oncology sales, could reshape the growth profile.
Johnson & Johnson has secured the first FDA approval for a treatment specifically targeting warm autoimmune hemolytic anemia, a rare and potentially deadly blood disorder. The drug, Imaavy, can now treat steroid-exposed adults and patients aged 12 or older. In clinical trials involving 115 adults, patients receiving Imaavy were approximately three times more likely than those on placebo to achieve sustained haemoglobin improvement after 24 weeks. The treatment also produced an average haemoglobin increase of one gramme per decilitre after the first week. Despite the regulatory milestone, J&J shares fell roughly 1% to $270.665 on Wednesday. The company generated $25.3 billion in second-quarter sales and raised its annual revenue midpoint to $101.1 billion, making this single indication unlikely to significantly impact near-term results.
A Louisiana jury awarded $10 million in a mesothelioma case linked to talc exposure, assigning Johnson & Johnson over $1.2 million of the liability. The jury found J&J's talc products unreasonably dangerous and inadequately labelled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson alongside a proposed $5.5 billion settlement aimed at resolving approximately 76,000 ovarian cancer claims. If the settlement proceeds with sufficient claimant participation, it could reduce legal uncertainty. Despite the legal challenges, Johnson & Johnson reported record quarterly sales supporting its Innovative Medicine and MedTech divisions. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth. Ongoing talc verdicts and potential follow-on cases continue to shape perceptions of the company's legal risk alongside its expanding medicines and MedTech portfolio.
The US Food and Drug Administration has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia in adults and children aged 12 and older. Johnson & Johnson announced the approval following FDA Priority Review. wAIHA is a rare, life-threatening condition where autoantibodies destroy red blood cells, causing severe anaemia and fatigue. Previously, only corticosteroids and immunosuppressants were available. The approval is based on the Phase 2/3 ENERGY study. Results showed approximately three times as many patients receiving IMAAVY achieved durable haemoglobin levels versus placebo by 24 weeks. Patients demonstrated a mean haemoglobin increase of 1 g/dL at Week 1. IMAAVY is an immunoselective FcRn blocker designed to reduce pathogenic IgG autoantibodies whilst preserving B-cell function. Common side effects included peripheral oedema, diarrhoea, and fever.